Current and Emerging Technologies for the Diagnosis of Microbial Infections /

• Άλλοι συγγραφείς: Sails, Andrew (Επιμελητής έκδοσης), Tang, Yi-Wei (Επιμελητής έκδοσης)
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: London : Academic Press, 2015.
• Σειρά: Methods in microbiology ; 42.
• Θέματα: Communicable diseases > Diagnosis.; Communicable diseases > Diagnosis > Technological innovations.; HEALTH & FITNESS > Diseases > General.; MEDICAL > Clinical Medicine.; MEDICAL > Diseases.; MEDICAL > Evidence-Based Medicine.; MEDICAL > Internal Medicine.; Communicable Diseases > diagnosis.; Electronic books.

Πίνακας περιεχομένων:

• Front Cover; Current and Emerging Technologies for the Diagnosis of Microbial Infections; Copyright; Contents; Contributors; Preface; Chapter 1: Total Laboratory Automation in Clinical Bacteriology; 1. Clinical Bacteriology and Automation: background; 2. Specimen Collection: liquid Microbiology; 3. Pre-analytical Automation; 4. Pre-analytical Bacteriology Specimen Plating Instruments; 4.1. Isoplater; 4.2. Innova; 4.3. BD Kiestra InoqulA+; 4.4. Previ Isola; 4.5. Copan WASP; 4.6. Prelude: i2a; 4.7. deltalab AUTOPLAK; 5. Digital Plate Reading; 6. TLA Systems; 6.1. BD Kiestra; 6.2. Copan WASPLab.
• 6.3. i2a: ECITALS7. Change Management: A Holistic Approach to Automation in Bacteriology; References; Chapter 2: MALDI-TOF Mass Spectrometry for Microorganism Identification; 1. Introduction; 1.1. MALDI-TOF MS: Principles and Processes; 1.2. Commercially Available MALDI-TOF MS Platforms; 1.3. Factors Influencing the Performance of MALDI-TOF MS; 2. Microbial Identification by MALDI-TOF MS; 2.1. Comparison of MALDI-TOF MS and Conventional Methods for the Identification of Routine Isolates; 2.2. Comparison of Commercially Available MALDI-TOF MS Systems.
• 2.3. Laboratory Cost Savings Associated with Using MALDI-TOF MS for Isolate Identification3. Performance of MALDI-TOF MS for the Identification of Routine Clinical Isolates; 3.1. Identification of Gram-Positive Bacteria; 3.2. Identification of Gram-Negative Bacteria; 3.3. Identification of Anaerobes; 3.4. Identification of Mycobacteria; 3.5. Identification of Yeast; 3.6. Identification of Filamentous Fungi; 3.7. Identification of Select Agents; 4. Direct Identification from Clinical Specimens; 4.1. Identification of Microorganisms Directly from Positive Blood Cultures.
• 4.2. Identification of Bacteria Directly from Urine Specimens4.3. Identification of Bacteria Directly from Cerebrospinal Fluid; Limitations and Conclusions; References; Chapter 3: POC Tests in Microbial Diagnostics: Current Status; 1. Introduction; 2. The Current Utilisation of Infectious Diseases POC Testing; 2.1. Viral Respiratory Infections; 2.2. HIV/AIDS, Tuberculosis, Sexually Transmitted Infections; 2.3. Diarrhoea and Gastrointestinal Diseases; 2.4. Surveillance, Prevention, and Diagnosis of Healthcare-Acquired Infections.
• 2.5. Anticipated POC Testing Advances Through Biomarkers or Improved Technologies2.5.1. Sepsis; 2.5.2. Technological advances in rapid immunochromatographic platforms; 2.5.3. Paper-based diagnostics; 2.6. Patient Empowerment Is Key for Any POC Test; 3. The Road to POC Molecular Diagnostics Is Paved with Good Intentions and Technologies; 3.1. Near-POC Testing; 3.2. Isothermal Amplification Technologies; 3.3. Integrated Molecular Diagnostics Platforms; 3.3.1. The GeneXpert® platform; 3.3.2. The GenePOC platform; Conclusions; Acknowledgements; References.